首页 > 最新文献

European journal of rheumatology最新文献

英文 中文
Engaging trainees within the virtual classroom: Teaching strategies for rheumatologists in a pandemic. 虚拟课堂中的学员参与:风湿病学家在大流行中的教学策略。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eujrheum.2022.20236
Stefanie D Wade, Jonathan S Hausmann, Jason A Freed

Social distancing during the COVID-19 pandemic has led to unprecedented challenges in medical education, including for rheumatology training programs. Many programs have adapted by transitioning educational curricula into virtual classrooms. Herein, we review strategies to optimize learning within the virtual classroom. We introduce the flipped virtual classroom as a framework for facilitating higher-order thinking and improving long-term learning. We provide recommendations to maximize interactions between learners, elevate group discussions, and encourage problem solving. Once implemented, these techniques can lead to more productive teaching and learning experiences while maintaining a sense of community for rheumatology training programs.

COVID-19大流行期间的社交距离给医学教育带来了前所未有的挑战,包括风湿病学培训计划。许多程序通过将教育课程过渡到虚拟教室来适应。在此,我们回顾了优化虚拟课堂学习的策略。我们引入翻转虚拟课堂作为促进高阶思维和改善长期学习的框架。我们提供建议,以最大限度地提高学习者之间的互动,提升小组讨论,并鼓励解决问题。一旦实施,这些技术可以带来更富有成效的教学和学习经验,同时保持风湿病学培训项目的社区意识。
{"title":"Engaging trainees within the virtual classroom: Teaching strategies for rheumatologists in a pandemic.","authors":"Stefanie D Wade,&nbsp;Jonathan S Hausmann,&nbsp;Jason A Freed","doi":"10.5152/eujrheum.2022.20236","DOIUrl":"https://doi.org/10.5152/eujrheum.2022.20236","url":null,"abstract":"<p><p>Social distancing during the COVID-19 pandemic has led to unprecedented challenges in medical education, including for rheumatology training programs. Many programs have adapted by transitioning educational curricula into virtual classrooms. Herein, we review strategies to optimize learning within the virtual classroom. We introduce the flipped virtual classroom as a framework for facilitating higher-order thinking and improving long-term learning. We provide recommendations to maximize interactions between learners, elevate group discussions, and encourage problem solving. Once implemented, these techniques can lead to more productive teaching and learning experiences while maintaining a sense of community for rheumatology training programs.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"148-152"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39778541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sonoelastrographic finding of Achilles tendon in patients with ankylosing spondylitis and acromegaly. 强直性脊柱炎和肢端肥大症患者跟腱的声像图表现。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eujrheum.2022.21132
Ahmet Karataş, Hakan Artaş, Kader Uğur, Süleyman Serdar Koca

Objectives: Achilles tendinopathy can be noticed in both acromegaly and ankylosing spondylitis (AS). Acromegaly patients presenting with tendinopathy findings may be confused with AS findings. In this study, sonoelastrographic findings of Achilles tendon are explored in patients with AS and acromegaly.

Methods: 25 patients with AS, 30 patients with acromegaly, and 18 healthy controls were enrolled in the study. Achilles tendon was evaluated by sonoelastography in all the study participants.

Results: The thickness of Achilles tendon in neutral positions was higher in acromegaly patients than those in AS patients. The sonoelastography measurement of Achilles tendon was increased in acromegaly patients when compared to the control group and AS patients.

Conclusion: The thickness of Achilles tendon can increase in patients with acromegaly and AS. However, the sonoelastographic features of Achilles tendon can be similar in patients with AS and acromegaly.

目的:肢端肥大症和强直性脊柱炎(AS)均可出现跟腱病变。肢端肥大症患者表现为肌腱病变可能与AS的表现相混淆。在本研究中,探讨了AS和肢端肥大症患者跟腱的声像图表现。方法:25例AS患者,30例肢端肥大症患者,18例健康对照。通过超声弹性成像评估所有研究参与者的跟腱。结果:肢端肥大症患者跟腱中性位厚度明显高于AS患者。与对照组和AS患者相比,肢端肥大症患者跟腱超声弹性测量增加。结论:肢端肥大症合并AS患者跟腱厚度增加。然而,AS和肢端肥大症患者跟腱的声像图特征是相似的。
{"title":"Sonoelastrographic finding of Achilles tendon in patients with ankylosing spondylitis and acromegaly.","authors":"Ahmet Karataş,&nbsp;Hakan Artaş,&nbsp;Kader Uğur,&nbsp;Süleyman Serdar Koca","doi":"10.5152/eujrheum.2022.21132","DOIUrl":"https://doi.org/10.5152/eujrheum.2022.21132","url":null,"abstract":"<p><strong>Objectives: </strong>Achilles tendinopathy can be noticed in both acromegaly and ankylosing spondylitis (AS). Acromegaly patients presenting with tendinopathy findings may be confused with AS findings. In this study, sonoelastrographic findings of Achilles tendon are explored in patients with AS and acromegaly.</p><p><strong>Methods: </strong>25 patients with AS, 30 patients with acromegaly, and 18 healthy controls were enrolled in the study. Achilles tendon was evaluated by sonoelastography in all the study participants.</p><p><strong>Results: </strong>The thickness of Achilles tendon in neutral positions was higher in acromegaly patients than those in AS patients. The sonoelastography measurement of Achilles tendon was increased in acromegaly patients when compared to the control group and AS patients.</p><p><strong>Conclusion: </strong>The thickness of Achilles tendon can increase in patients with acromegaly and AS. However, the sonoelastographic features of Achilles tendon can be similar in patients with AS and acromegaly.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"122-125"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39778540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pustulotic arthro-osteitis (Sonozaky syndrome). 脓疱性关节骨炎(索诺扎基综合征)。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eujrheum.2022.21127
Grigorios T Sakellariou, Ioannis Tsifountoudis
{"title":"Pustulotic arthro-osteitis (Sonozaky syndrome).","authors":"Grigorios T Sakellariou,&nbsp;Ioannis Tsifountoudis","doi":"10.5152/eujrheum.2022.21127","DOIUrl":"https://doi.org/10.5152/eujrheum.2022.21127","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"180-181"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39792799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of endothelial function in patients with Behçet's disease in remission: A cross-sectional study. behaperet病缓解期患者内皮功能的评估:一项横断面研究。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eujrheum.2022.20184
Fernanda Mendonça Rodrigues, Ana Beatriz Bacchiega, Bruno Cesar Bacchiega, Manuella Lima Gomes Ochtrop, Roger Abramino Levy

Objective: Endothelial dysfunction is an initial stage of the atherogenic process, which can be evaluated by a noninvasive method (flow-mediated dilation - FMD) and has a well-established prognostic value for cardiovascular (CV) risk. Currently, there is no evidence of increased CV mortality in Behc¸et's disease (BD), although its association with endothelial dysfunction has been described. There are still doubts in the literature whether the presence of chronic vascular inflammation might trigger the development of atherosclerosis, despite BD remission, which is why this study was conducted.

Methods: We analyzed 24 subjects in this cross-sectional study (12 patients with BD in remission and 12 subjects matched by gender age). Endothelial function was analyzed via FMD.

Results: The lowest median for FMD was presented by the BD group (2.025% - interquartile range (IQR) 7.785 versus 5.46% - IQR 3.625, P ¼ .18). The median total cholesterol in the BD group was lower than the controls (168 mg dL-1 - IQR 46 and 216.5 mg dL-1 - IQR 54, respectively, P ¼ .0193). In the right carotid artery, the intima-media thickness was equal to 0.740 - IQR 0.16 for the patients and 0.740 - IQR 0.11 for the controls (P ¼ .9473); on the left, 0.725 - IQR 0.13 and 0.745 - IQR 0.120 (P ¼ .4333), respectively.

Conclusion: The lower median trend of FMD in patients with BD suggests endothelial dysfunction, despite clinical remission of the inflammatory disease, although our study is limited by the sample size and greater use of statins in BD group.

目的:内皮功能障碍是动脉粥样硬化过程的初始阶段,可以通过无创方法(血流介导扩张- FMD)进行评估,并具有良好的心血管(CV)风险预后价值。目前,没有证据表明Behc - et病(BD)的心血管死亡率增加,尽管其与内皮功能障碍的关联已被描述。尽管BD缓解,但文献中仍存在慢性血管炎症是否会引发动脉粥样硬化的疑问,这也是本研究开展的原因。方法:我们在这项横断面研究中分析了24名受试者(12名缓解期BD患者和12名性别年龄匹配的受试者)。通过FMD分析内皮功能。结果:BD组FMD的中位数最低(2.025% -四分位差(IQR) 7.785比5.46% - IQR 3.625, P < 0.18)。BD组的中位总胆固醇低于对照组(分别为168 mg dL-1 - IQR 46和216.5 mg dL-1 - IQR 54, P < 0.0193)。右颈动脉内膜-中膜厚度,患者为0.740 - IQR 0.16,对照组为0.740 - IQR 0.11 (P = 0.9473);左侧分别为0.725 - IQR 0.13和0.745 - IQR 0.120 (P¼.4333)。结论:尽管炎症性疾病的临床缓解,但BD患者FMD的中位趋势较低表明内皮功能障碍,尽管我们的研究受到BD组样本量和他汀类药物使用较多的限制。
{"title":"Evaluation of endothelial function in patients with Behçet's disease in remission: A cross-sectional study.","authors":"Fernanda Mendonça Rodrigues,&nbsp;Ana Beatriz Bacchiega,&nbsp;Bruno Cesar Bacchiega,&nbsp;Manuella Lima Gomes Ochtrop,&nbsp;Roger Abramino Levy","doi":"10.5152/eujrheum.2022.20184","DOIUrl":"https://doi.org/10.5152/eujrheum.2022.20184","url":null,"abstract":"<p><strong>Objective: </strong>Endothelial dysfunction is an initial stage of the atherogenic process, which can be evaluated by a noninvasive method (flow-mediated dilation - FMD) and has a well-established prognostic value for cardiovascular (CV) risk. Currently, there is no evidence of increased CV mortality in Behc¸et's disease (BD), although its association with endothelial dysfunction has been described. There are still doubts in the literature whether the presence of chronic vascular inflammation might trigger the development of atherosclerosis, despite BD remission, which is why this study was conducted.</p><p><strong>Methods: </strong>We analyzed 24 subjects in this cross-sectional study (12 patients with BD in remission and 12 subjects matched by gender age). Endothelial function was analyzed via FMD.</p><p><strong>Results: </strong>The lowest median for FMD was presented by the BD group (2.025% - interquartile range (IQR) 7.785 versus 5.46% - IQR 3.625, P ¼ .18). The median total cholesterol in the BD group was lower than the controls (168 mg dL-1 - IQR 46 and 216.5 mg dL-1 - IQR 54, respectively, P ¼ .0193). In the right carotid artery, the intima-media thickness was equal to 0.740 - IQR 0.16 for the patients and 0.740 - IQR 0.11 for the controls (P ¼ .9473); on the left, 0.725 - IQR 0.13 and 0.745 - IQR 0.120 (P ¼ .4333), respectively.</p><p><strong>Conclusion: </strong>The lower median trend of FMD in patients with BD suggests endothelial dysfunction, despite clinical remission of the inflammatory disease, although our study is limited by the sample size and greater use of statins in BD group.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"139-143"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39792800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Tracheobronchopathia osteochondroplastica and cervical spine involvement in rheumatoid arthritis. 气管支气管病变、骨软骨增生和颈椎累及类风湿关节炎。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eurjrheum.2022.21033
Nurbanu Hindioğlu, Mahmut Bilal Doğan, Meryem Can
Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm.
{"title":"Tracheobronchopathia osteochondroplastica and cervical spine involvement in rheumatoid arthritis.","authors":"Nurbanu Hindioğlu,&nbsp;Mahmut Bilal Doğan,&nbsp;Meryem Can","doi":"10.5152/eurjrheum.2022.21033","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.21033","url":null,"abstract":"Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm.","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"182-183"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39623309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Features predicting colchicine efficacy in treatment of children with undefined systemic autoinflammatory disease: A retrospective cohort study. 预测秋水仙碱治疗不明全身性自身炎症性疾病的疗效:一项回顾性队列研究。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eurjrheum.2022.21135
Mariana Correia Marques, Buğra Han Egeli, Holly Wobma, Claudio Ribeiro, Edwin Anderson, Jonathan S Hausmann, Fatma Dedeoğlu

Objective: Patients with undefined systemic autoinflammatory diseases (uSAIDs) are challenging to manage, as there are no guidelines or recommendations for targeted therapy. We aimed to evaluate the efficacy of empiric treatment with colchicine in our single-center uSAID population in the United States, as well as the patient characteristics associated with the most robust colchicine response.

Methods: Children with uSAID 18 years old at initial evaluation during 2000-2019 were included if they received 3 months of colchicine therapy. Data on demographics, clinical features, laboratory/ genetic studies, and treatment responses were collected. Most statistics were based on chi-square analyses for categorical data. Complete response to colchicine was defined as resolution of episodes or the presence of minor residual symptoms that did not require any further therapy. A partial response was defined as a decrease in the frequency, severity, or length of episodes but still necessitating additional therapy. Patients were considered nonresponders if they did not experience any improvement with colchicine at target therapeutic dosing.

Results: We identified 133 children diagnosed with uSAID who met our inclusion criteria. The median time to starting empiric colchicine was 5 months from the diagnosis of autoinflammatory disease. 92.5% (n = 123) of patients had a beneficial response to colchicine, including 46.6% (n = 62) partial responders and 45.9% (n = 61) complete responders. The presence of a nonurticarial rash was associated with an incomplete colchicine response (29.2% (n = 21) vs 13.1% (n = 8), P = .025). The presence of a heterozygous MEFV mutation in patients who did not fit Familial Mediterranean Fever diagnostic criteria (n = 25) appeared to be associated with a greater likelihood of complete colchicine response, although this was not statistically significant (62.5% (n = 14) vs 42.6% (n =11), P = .08). In MEFV mutation-negative patients, a nonurticarial rash was even more strongly associated with incomplete colchicine response, with an OR of 27.53 (CI [1.59-477], P = .023). The presence of oral ulcers also corresponded to incomplete colchicine response, although this did not reach clinical significance (38.9% (n = 28) vs 24.6% (n = 15), P = .08). There was no significant association between episode duration or frequency and colchicine response.

Conclusion: Colchicine leads to clinical benefits in most children with uSAID. We, thus, recommend an early trial of colchicine in newly diagnosed patients with uSAID.

目的:不明全身性自身炎症性疾病(uSAIDs)患者的治疗具有挑战性,因为没有针对靶向治疗的指南或建议。我们的目的是评估秋水仙碱经验性治疗在美国uSAID单中心人群中的疗效,以及与秋水仙碱反应最强相关的患者特征。方法:纳入2000-2019年初始评估时患有uSAID的18岁儿童,如果他们接受了3个月的秋水仙碱治疗。收集了人口统计学、临床特征、实验室/遗传学研究和治疗反应的数据。大多数统计是基于卡方分析的分类数据。秋水仙碱完全缓解被定义为不需要任何进一步治疗的发作缓解或轻微残留症状的存在。部分缓解被定义为发作频率、严重程度或时间减少,但仍需要额外治疗。如果在目标治疗剂量下秋水仙碱没有任何改善,则认为患者无反应。结果:我们确定了133名被诊断患有uSAID的儿童,他们符合我们的纳入标准。从诊断为自身炎症性疾病到开始使用秋水仙碱的中位时间为5个月。92.5% (n = 123)的患者对秋水仙碱有有益反应,其中46.6% (n = 62)的患者部分缓解,45.9% (n = 61)的患者完全缓解。非荨麻疹的出现与秋水仙碱反应不完全相关(29.2% (n = 21) vs 13.1% (n = 8), P = 0.025)。在不符合家族性地中海热诊断标准的患者(n = 25)中存在杂合MEFV突变似乎与更大的秋水草碱完全反应的可能性相关,尽管这没有统计学意义(62.5% (n = 14) vs 42.6% (n =11), P = 0.08)。在MEFV突变阴性的患者中,非荨麻疹皮疹与秋水仙碱不完全反应的相关性更强,OR为27.53 (CI [1.59-477], P = 0.023)。口腔溃疡的存在也与秋水仙碱反应不完全相关,尽管这没有达到临床意义(38.9% (n = 28) vs 24.6% (n = 15), P = 0.08)。发作持续时间或频率与秋水仙碱反应之间无显著关联。结论:秋水仙碱对大多数患有uSAID的儿童有临床益处。因此,我们建议在新诊断的uSAID患者中进行秋水仙碱的早期试验。
{"title":"Features predicting colchicine efficacy in treatment of children with undefined systemic autoinflammatory disease: A retrospective cohort study.","authors":"Mariana Correia Marques,&nbsp;Buğra Han Egeli,&nbsp;Holly Wobma,&nbsp;Claudio Ribeiro,&nbsp;Edwin Anderson,&nbsp;Jonathan S Hausmann,&nbsp;Fatma Dedeoğlu","doi":"10.5152/eurjrheum.2022.21135","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.21135","url":null,"abstract":"<p><strong>Objective: </strong>Patients with undefined systemic autoinflammatory diseases (uSAIDs) are challenging to manage, as there are no guidelines or recommendations for targeted therapy. We aimed to evaluate the efficacy of empiric treatment with colchicine in our single-center uSAID population in the United States, as well as the patient characteristics associated with the most robust colchicine response.</p><p><strong>Methods: </strong>Children with uSAID 18 years old at initial evaluation during 2000-2019 were included if they received 3 months of colchicine therapy. Data on demographics, clinical features, laboratory/ genetic studies, and treatment responses were collected. Most statistics were based on chi-square analyses for categorical data. Complete response to colchicine was defined as resolution of episodes or the presence of minor residual symptoms that did not require any further therapy. A partial response was defined as a decrease in the frequency, severity, or length of episodes but still necessitating additional therapy. Patients were considered nonresponders if they did not experience any improvement with colchicine at target therapeutic dosing.</p><p><strong>Results: </strong>We identified 133 children diagnosed with uSAID who met our inclusion criteria. The median time to starting empiric colchicine was 5 months from the diagnosis of autoinflammatory disease. 92.5% (n = 123) of patients had a beneficial response to colchicine, including 46.6% (n = 62) partial responders and 45.9% (n = 61) complete responders. The presence of a nonurticarial rash was associated with an incomplete colchicine response (29.2% (n = 21) vs 13.1% (n = 8), P = .025). The presence of a heterozygous MEFV mutation in patients who did not fit Familial Mediterranean Fever diagnostic criteria (n = 25) appeared to be associated with a greater likelihood of complete colchicine response, although this was not statistically significant (62.5% (n = 14) vs 42.6% (n =11), P = .08). In MEFV mutation-negative patients, a nonurticarial rash was even more strongly associated with incomplete colchicine response, with an OR of 27.53 (CI [1.59-477], P = .023). The presence of oral ulcers also corresponded to incomplete colchicine response, although this did not reach clinical significance (38.9% (n = 28) vs 24.6% (n = 15), P = .08). There was no significant association between episode duration or frequency and colchicine response.</p><p><strong>Conclusion: </strong>Colchicine leads to clinical benefits in most children with uSAID. We, thus, recommend an early trial of colchicine in newly diagnosed patients with uSAID.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"116-121"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39623313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Undetectable mannose binding lectin confers increased risk for serious infection in rheumatoid arthritis. 无法检测到的甘露糖结合凝集素会增加类风湿关节炎严重感染的风险。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eurjrheum.2021.21071
Graeme J Carroll
Physical activity and psychosomatic status in patients with Behçet's disease during coronavirus disease pandemic.
{"title":"Undetectable mannose binding lectin confers increased risk for serious infection in rheumatoid arthritis.","authors":"Graeme J Carroll","doi":"10.5152/eurjrheum.2021.21071","DOIUrl":"https://doi.org/10.5152/eurjrheum.2021.21071","url":null,"abstract":"Physical activity and psychosomatic status in patients with Behçet's disease during coronavirus disease pandemic.","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"184"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39623310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease. 类风湿关节炎相关间质性肺疾病的抗纤维化治疗。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-07-01 DOI: 10.5152/eurjrheum.2021.21102
Cemal Bes, Gizem Köybaşı, Ozan Cemal İçaçan, Melek Yalçın Mutlu, Fatih Yıldırım

Interstitial lung disease (ILD) is one of the common extra-articular manifestations of rheumatoid arthritis (RA) and it is associated with high mortality rate. The usual interstitial pneumonia (UIP) pattern of RA associated ILD (RA-ILD) shows some similarities to idiopathic pulmonary fibrosis, suggesting that antifibrotic therapies may have potential positive affects. In this review, we discuss the effectiveness of antifibrotic therapy for RA-ILD.

间质性肺疾病(ILD)是类风湿性关节炎(RA)常见的关节外表现之一,死亡率高。RA相关ILD (RA-ILD)的常见间质性肺炎(UIP)模式与特发性肺纤维化有一些相似之处,提示抗纤维化治疗可能具有潜在的积极作用。在这篇综述中,我们讨论抗纤维化治疗对RA-ILD的有效性。
{"title":"Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease.","authors":"Cemal Bes,&nbsp;Gizem Köybaşı,&nbsp;Ozan Cemal İçaçan,&nbsp;Melek Yalçın Mutlu,&nbsp;Fatih Yıldırım","doi":"10.5152/eurjrheum.2021.21102","DOIUrl":"https://doi.org/10.5152/eurjrheum.2021.21102","url":null,"abstract":"<p><p>Interstitial lung disease (ILD) is one of the common extra-articular manifestations of rheumatoid arthritis (RA) and it is associated with high mortality rate. The usual interstitial pneumonia (UIP) pattern of RA associated ILD (RA-ILD) shows some similarities to idiopathic pulmonary fibrosis, suggesting that antifibrotic therapies may have potential positive affects. In this review, we discuss the effectiveness of antifibrotic therapy for RA-ILD.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 3","pages":"176-179"},"PeriodicalIF":1.9,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39623312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparison of rituximab with cyclophosphamide in terms of efficacy and complications as induction therapy for treating granulomatosis with polyangiitis: A three-center study. 利妥昔单抗与环磷酰胺诱导治疗肉芽肿合并多血管炎的疗效及并发症比较:一项三中心研究。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-04-01 DOI: 10.5152/eurjrheum.2022.21063
Maryam Tavakoli Chaleshtori, Ziba Farajzadegan, Mansour Salesi

Objective: Granulomatosis with polyangiitis (GPA), formerly known as Wegner's granulomatosis, is a rare vasculitic syndrome classified under Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA)-associ- ated vasculitides, which is fatal if untreated. The mainstay of treatment consists of immunosuppression using a combination of corticosteroids with either rituximab (RTX) or cyclophosphamide (CYC). We aimed to compare the 4-year clinical outcomes between patients with GPA receiving CYC and RTX as remission induction.

Methods: In this retrospective cohort, we used patient data from 92 patients with GPA at two large teaching hospitals and a private clinic in Isfahan, Iran. The patients were classified based on the medi- cation they received for remission induction into RTX and CYC groups. The main outcomes were rate of death and relapse, disease activity assessed based on the Birmingham Vasculitis Activity Score (BVAS), disease-related complications, laboratory markers, and adverse-drug-reactions.

Results: Fifty-three (57.6%) patients received CYC, whereas 39 (42.4%) received RTX. The mean duration of follow-up was 3.6 (62) years. Most of patients (70%) had a successful remission, while 20.7% experi- enced a relapse and 8.7% of patients died. The rate of death and relapse did not differ between the RTX and CYC groups. Disease-related complications involved an insignificantly higher proportion of patients in the CYC (12/53) group than the RTX (4/39) group. Patients in both groups showed a signifi- cant decrease in BVAS during follow-ups irrespective of the medication exposure. The rate of adverse events was similarly low (n 1⁄4 1) in both groups.

Conclusion: RTX and CYC were similar in inducing remission and reducing adverse clinical outcomes among patients with GPA with acceptable side effect profiles.

目的:肉芽肿病合并多血管炎(GPA),以前称为韦格纳肉芽肿病,是一种罕见的血管增生综合征,属于抗中性粒细胞自身抗体(ANCA)相关的血管增生,如果不治疗是致命的。主要的治疗包括免疫抑制,使用糖皮质激素联合利妥昔单抗(RTX)或环磷酰胺(CYC)。我们的目的是比较接受CYC和RTX作为缓解诱导的GPA患者的4年临床结果。方法:在这个回顾性队列研究中,我们使用了来自伊朗伊斯法罕两家大型教学医院和一家私人诊所的92名GPA患者的患者资料。根据患者接受的缓解诱导药物分为RTX组和CYC组。主要结局是死亡率和复发率、基于伯明翰血管炎活动度评分(BVAS)评估的疾病活动度、疾病相关并发症、实验室标志物和药物不良反应。结果:53例(57.6%)患者接受CYC治疗,39例(42.4%)患者接受RTX治疗。平均随访时间为3.6(62)年。大多数患者(70%)成功缓解,20.7%复发,8.7%死亡。RTX组和CYC组之间的死亡率和复发率没有差异。CYC(12/53)组的疾病相关并发症发生率不显著高于RTX(4/39)组。两组患者在随访期间均显示BVAS显著下降,与药物暴露无关。两组不良事件发生率同样低(n 1 / 4 1)。结论:在副作用可接受的GPA患者中,RTX和CYC在诱导缓解和减少不良临床结局方面相似。
{"title":"A comparison of rituximab with cyclophosphamide in terms of efficacy and complications as induction therapy for treating granulomatosis with polyangiitis: A three-center study.","authors":"Maryam Tavakoli Chaleshtori,&nbsp;Ziba Farajzadegan,&nbsp;Mansour Salesi","doi":"10.5152/eurjrheum.2022.21063","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.21063","url":null,"abstract":"<p><strong>Objective: </strong>Granulomatosis with polyangiitis (GPA), formerly known as Wegner's granulomatosis, is a rare vasculitic syndrome classified under Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA)-associ- ated vasculitides, which is fatal if untreated. The mainstay of treatment consists of immunosuppression using a combination of corticosteroids with either rituximab (RTX) or cyclophosphamide (CYC). We aimed to compare the 4-year clinical outcomes between patients with GPA receiving CYC and RTX as remission induction.</p><p><strong>Methods: </strong>In this retrospective cohort, we used patient data from 92 patients with GPA at two large teaching hospitals and a private clinic in Isfahan, Iran. The patients were classified based on the medi- cation they received for remission induction into RTX and CYC groups. The main outcomes were rate of death and relapse, disease activity assessed based on the Birmingham Vasculitis Activity Score (BVAS), disease-related complications, laboratory markers, and adverse-drug-reactions.</p><p><strong>Results: </strong>Fifty-three (57.6%) patients received CYC, whereas 39 (42.4%) received RTX. The mean duration of follow-up was 3.6 (62) years. Most of patients (70%) had a successful remission, while 20.7% experi- enced a relapse and 8.7% of patients died. The rate of death and relapse did not differ between the RTX and CYC groups. Disease-related complications involved an insignificantly higher proportion of patients in the CYC (12/53) group than the RTX (4/39) group. Patients in both groups showed a signifi- cant decrease in BVAS during follow-ups irrespective of the medication exposure. The rate of adverse events was similarly low (n 1⁄4 1) in both groups.</p><p><strong>Conclusion: </strong>RTX and CYC were similar in inducing remission and reducing adverse clinical outcomes among patients with GPA with acceptable side effect profiles.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 2","pages":"88-92"},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b3/4b/ejr-9-2-88.PMC10176214.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9447635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry. 风湿病患者生物治疗的现实分析:来自TURKBIO登记处的数据。
IF 1.9 Q4 RHEUMATOLOGY Pub Date : 2022-04-01 DOI: 10.5152/eurjrheum.2022.21060
Fatoş Önen, Gerçek Can, Sedat Çapar, Ediz Dalkılıç, Yavuz Pehlivan, Soner Şenel, Servet Akar, Süleyman Serdar Koca, Abdurrahman Tufan, Ayten Yazıcı, Sema Yılmaz, Nevsun İnanç, İsmail Sarı, Merih Birlik, Dilek Solmaz, Ayşe Cefle, Mehmet Akif Öztürk, Servet Yolbaş, Niels Steen Krogh, Neslihan Yılmaz, Şükran Erten, Cemal Bes, Özgül Soysal Gündüz, Berna Göker, Seminur Haznedaroğlu, Şule Yavuz, Gözde Yildirim Çetin, Fatih Yıldız, Haner Direskeneli, Nurullah Akkoç

Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018.

Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens.

Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31.

Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.

TURKBIO登记处成立于2011年,是土耳其第一个全国性的生物数据库。本研究旨在提供截至2018年6月收集的TURKBIO数据的概述。方法:登记包括类风湿关节炎(RA),强直性脊柱炎(AS),非放射性轴性脊柱炎(nr-AxSpA)和银屑病关节炎(PsA)的成年患者。人口统计学和临床特征、疾病活动标志物和其他随访参数、当前和以前的治疗以及不良事件在每次就诊时使用开源软件进行电子登记。患者报告的结果测量的登记由患者使用触摸屏进行电子登记。TURKBIO注册表共包括41,145个生物制剂治疗系列。有2588例axSpA患者(2459例AS和129例nr-axSpA), 2036例RA和428例PsA。包括其他诊断在内的患者总数为5718人。在随访期间,患者数量和访问量逐年稳步增加。每位患者的年平均就诊次数为2.3次。生物治疗后,疾病活动性和健康评估参数显著改善。在RA患者中,生物制剂通常与传统的合成疾病改善抗风湿药物联合使用。感染是最常见的不良反应,其次是过敏反应。结核病12例,恶性肿瘤18例,治疗相关死亡31例。结论:TURKBIO为土耳其风湿病患者使用生物制剂提供了宝贵的现实经验。
{"title":"A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.","authors":"Fatoş Önen,&nbsp;Gerçek Can,&nbsp;Sedat Çapar,&nbsp;Ediz Dalkılıç,&nbsp;Yavuz Pehlivan,&nbsp;Soner Şenel,&nbsp;Servet Akar,&nbsp;Süleyman Serdar Koca,&nbsp;Abdurrahman Tufan,&nbsp;Ayten Yazıcı,&nbsp;Sema Yılmaz,&nbsp;Nevsun İnanç,&nbsp;İsmail Sarı,&nbsp;Merih Birlik,&nbsp;Dilek Solmaz,&nbsp;Ayşe Cefle,&nbsp;Mehmet Akif Öztürk,&nbsp;Servet Yolbaş,&nbsp;Niels Steen Krogh,&nbsp;Neslihan Yılmaz,&nbsp;Şükran Erten,&nbsp;Cemal Bes,&nbsp;Özgül Soysal Gündüz,&nbsp;Berna Göker,&nbsp;Seminur Haznedaroğlu,&nbsp;Şule Yavuz,&nbsp;Gözde Yildirim Çetin,&nbsp;Fatih Yıldız,&nbsp;Haner Direskeneli,&nbsp;Nurullah Akkoç","doi":"10.5152/eurjrheum.2022.21060","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.21060","url":null,"abstract":"<p><strong>Objective: </strong>TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018.</p><p><strong>Methods: </strong>The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens.</p><p><strong>Results: </strong>TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31.</p><p><strong>Conclusion: </strong>TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 2","pages":"82-87"},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/02/ejr-9-2-82.PMC10176217.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9447689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
European journal of rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1